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Abstract 
Introduction: As many as 30% of node-negative breast cancer patients relapse within five years, suggesting that 
current histological detection methods are inadequate for identifying metastatic disease. Detecting small number of 
cancer cells in the breast tissue or lymph node by reverse transcription-polymerase chain reaction (RT-PCR) assays 
using a combination of tissue and cancer specific markers might be very useful in the early detection or monitoring 
of the treatment. Mammaglobin is a member of the uteroglobin gene family and appears to be expressed only in 
breast tissue. Carcinoembryonic antigen has been the preferred molecular marker for detection of micro metastases 
in lymph nodes in almost all carcinomas. Materials and Methods: Samples were collected from randomly chosen 
breast cancer patients undergoing modified mastectomy or breast conserving surgery between September 2003 and 
July 2004. RT-PCR was applied to study the expression of MMG and CEA markers. Breast cancer micrometastases 
in axillary lymph nodes were also assessed. Results: The MMG marker was positive in 9/10 normal breast tissues, 3/ 
3 breast fibroadenomas and 37/39 of breast carcinoma tissues, giving an overall sensitivity of 94%. The sensitivity 
was 80% for metastatic lymph node samples. On the other hand CEA showed 95% sensitivity for malignant breast 
tumors and 100% sensitivity for metastatic lymph nodes. Conclusions: RT-PCR using a combination of MMG and 
CEA markers is a powerful tool to complement current routine histopathology techniques for detection of breast 
cancer metastasis in axillary nodes. 
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In Study Group, 1990) that was not detected by routine 
histopathologic examination (Aihara et al., 1999). 
Reverse transcription-polymerase chain reaction (RT­
PCR) assays using tissue or cancer-specific gene transcripts 
(tumor markers) have been reported to constitute a sensitive 
method for detection of breast cancer dissemination in 
axillary lymph nodes (Duffy, 2001). Since most tumor 
markers in clinical practice lack organ specificity (Watson 
et al., 1994) combining several markers may be more 
promising for improving the incidence of cancer detection 
(Duffy, 2001). Mammaglobin is a member of the uteroglobin 
gene family, which is localized on human chromosome 
11q13 and appears to be expressed only in breast tissue (Jnku 
et al, 2004; Marchetti et al., 2001). Mammoglobin messenger 
RNA expression has been reported in 70% to 95% of primary 
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troduction 
Breast cancer is one of the most common cancers in 
women, and is rapidly increasing in incidence and death 
rate (Sloane et al., 1980; Branagan et al., 2002). Detecting 
small number of cancer cells in the breast tissue or lymph 
node might be very useful in the early detection or 
monitoring of the treatment (Sloane et al., 1980; Yeu-Tsu, 
1994) As many as 30% of patients with breast cancer who 
have undergone curative surgery and show no evidence of 
locoregional or distant disease still have recurrent disease 
over 5-10 years (Hellman, 1994; International (Ludwig) 
Breast Cancer Study Group, 1990). Some of these treatment 
failures may be attributed to residual disease in the breast or 
axillary lymph nodes (International (Ludwig) Breast Cancer 
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 Detection of Breast Cancer Micrometastasis by RT-PCR for CEA and Mammaglobulin 
and metastatic breast tumor biopsies (Leygue et al., 1999; 
Masuda et al., 2000). Carcinoembryonic antigen has been 
the preferred molecular marker for detection of 
micrometastases in lymph nodes in almost all carcinomas. 
However, some evidence suggests that false positives may 
arise in some situations (Masuda et al., 2000). It has been 
shown that both of MMG and CEA are appropriate tumor 
markers, consistently expressed in tumor but not normal 
lymph nodes (Marchetti et al., 2001). In the present study, 
we applied a combination of mammaglobin (MMG) and 
carcinoembryonic antigen (CEA) genes for the detection of 
breast cancer micrometastases in axillary lymph nodes. 
Materials and Methods 
Patients and sample collection 
Samples were collected from 59 randomly chosen breast 
cancer patients undergone modified mastectomy or breast 
conserving surgery between September 2003 and July 2004. 
They included 52 breast tumor samples (3 fibroadenoma, 
10 nonmalignant breast tissue, 39 breast carcinoma) and 13 
axillary lymph node samples (5 metastatic, 8 non-metastatic). 
One half of each axillary lymph node was formalin fixed 
and embedded for routine histological examination by 
hematoxylin and eosin (H&E) staining. The other half of 
the lymph nodes and malignant and nonmalignant breast 
tissues were stored at 4˚C for a short period (usually between 
12-24h) until RNA extraction. 
RNA extraction 
Total RNA was extracted with a single-step method 
(Greenberg et al., 2003) from surgical and pathological 
specimens using TriPure Isolation Reagent (Roche Applied) 
according to the manufacture’s protocol. Fresh tissue 
specimens were cut into small pieces with clean surgical 
knives to avoid RNA degradation. 
Multiplex RT-PCR assay 
Complementary DNA (cDNA) was generated with 
moloney murine leukemia virus reverse transcriptase 
(Invitrogen life technologies) according to the manufacture’s 
protocol. Briefly, 1µg of RNA was incubated at 65˚C for 5 
min and then put on ice for at least 2 min before the addition 
of RT reaction reagents with Oligo-(dT) 18 (0.5¬µg/¬µl) 
priming. The RT reaction was performed at 37˚C for 5 min 
and 42˚C for 55 min, followed by heating at 70˚C for 10 
min and 4˚C for 2 min. 
Multiplex PCR was performed in a 50µl reaction mixture 
containing 5µl cDNA template, 1X Biotools PCR buffer, 
1.5 mM MgCl , 1mM deoxynucleotide triphosphates,0.2 µM 
2
of each primer, and 2 units of Taq DNA polymerase 5u/µl 
(Biotools DNA polymerase).The PCR condition was initial 
denaturing at 94˚C for 5min, followed by 35 cycles at 95˚C 
for 0.5min, 60˚C for 0.5 min, 68˚C for 2.5 min, and for final 
extension 68˚C for 5 min. The primer sequences used for 
actin, mammaglobin and carcinomaembryionic antigen 
cDNA detection are shown in Table 1. The integrity of all 
Table 1. Sequences of Actin, MMG, and CEA Primers 
Primer Sequence (5’-3’)  Size (bp) 
Actin MP1  5’-CTC-TTC-CAG-CCT-TCC-TTC-CT-3 
Actin MP2     5’-AGC-ACT-GTG-TTG-GCG-AC-G-3         115 
Hellman 1994 
MMG D2        5’- GAC-ATA-AGA-AAG -AGA-AGG-TGT GG 3 
MMG D2102 5’- CAG-CGG-CTT-CCT-TGA-TCC-TTG 3  430 
Branagan et al., 2002 
CEA forward 5’- GAG-CGA-ACC-TCA-ACC-TCT-CCT-GCC-ACT-3 
CEA reverse 5’-TGT-AGC-TGT-TGC-AAA-TGC-TTT-AAG-GAA-GAA GC-3’   366 
Masuda et al., 2000 
RNA samples was verified by amplification of actin mRNA 
by RT-PCR. 
Results 
Validation of markers 
Eight breast tissue samples, 3 with malignant findings 
and 5 with normal histopathology, together with 2 
pathologically malignant lymph nodes were used to establish 
the validity of MMG and CEA markers for the detection of 
breast tissue and breast cancer metastases. MMG was 
positive in all breast tissues as well as metastatic lymph 
nodes. On the other hand CEA was positive in all known 
malignant tissues and negative in normal ones. Actin which 
had been used as positive control was positive in all samples. 
These markers were selected on the basis of their previously 
reported specificity for normal breast tissues and breast 
cancer metastases in lymph nodes (International (Ludwig) 
Breast Cancer Study Group, 1990; Masuda N. et al., 2000). 
Detection of micrometastases: comparison between CEA RT­
PCR and MMG RT-PCR 
A total of 1022 tissue samples from 59 breast cancer 
patients were analyzed using RT-PCR for expression of the 
validated markers. All patients were females, aged 19 to 88 
(mean 47.5). The actin mRNA message was used as positive 
control in all experiments. Two samples which had negative 
results for actin were excluded from this study. The 
distribution of MMG and CEA positivity in nonmalignant 
breast tissues, fibroadenomas, primary breast cancers and 
metastatic and nonmetastatic lymph nodes is summarized 
in Table 2. Of 10 patients with non-malignant breast tissues, 
9 had samples with MMG positive results. There was one 
CEA positive result among samples obtained from 
histologically non-malignant breast tissues samples. 
However 1 out of 9 axillary nodes in this patient was 
histologically positive. Of 39 patients affected with breast 
carcinoma, 37 were MMG positive. Among MMG positive 
patients, 2 were CEA negative. On the other hand, 37 patients 
were CEA positive among which 2 were MMG negative. 
Thus, all malignant breast tissue samples were either MMG 
or CEA positive. Five histologically positive and 8 
histologically negative node patients were studied. All 
histologically positive nodes were CEA positive and 4 were 
MMG positive. In one histologically negative lymph node 
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 Table 2. MMG, CEA and B-ACTIN mRNAs in Non­
malignant Breast Tissues, Fibroadenomas, Primary 
Breast Cancers and Axillary Lymph Nodes (LN)
 MMG +  CEA+  MMG+/CEA+ 
Tissue/pathology n  n (%)  n (%) n (%) 
Breast/normal 10  9 (90)  1 (10)  9 (90) 
Breast/Fibroadenoma  3  3 (100)  0 (0)  3 (100) 
Breast/carcinoma 39 37 (95) 37 (95) 39 (100) 
LN/metastatic  5  4 (80)  5 (100)  5 (100) 
LN/Non-metastatic  8  2 (25)  3 (38)  3 (38) 
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CEA was positive. Moreover, in 2 histologically negative 
lymph nodes, both MMG and CEA were positive. All these 
3 patients had breast carcinomas. 
Discussion 
To date, several studies have been performed to find 
appropriate tumor markers for breast cancer (Yeu-Tsu, 1994; 
Duffy, 2001). In the present study, we obtained a 94% 
sensitivity for the MMG marker overall and 80% for 
metastatic lymph nodes. CEA showed a 95% sensitivity for 
malignant breast tumors and 100% sensitivity for metastatic 
lymph nodes. Our finding of the absence of MMG marker 
expression in the 1 of 10 normal tissue samples is in 
accordance with similar earlier studies (Jnku et al., 2004; 
Watson et al., 1996). The fact that two out of 39 malignant 
samples showed no MMG expression may be explained by 
a lack of expression with advanced malignancies (Min et 
al., 1998; Masuda et al., 2000). 
Our results are furthermore indicative of a higher 
sensitivity of these molecular markers for detection of 
micrometastases than standard histopathology. The 10-year 
disease-free and overall survival rates may be significantly 
better in patients without micrometastases (Chomczynski 
et al., 1987). However, the clinical and prognostic 
significance of our results need to be further investigated in 
a prospective study on a larger number of breast cancer 
patients. Obtaining lymph nodes for RT-PCR experiments 
is difficult due to the ethical concerns regarding use for a 
research only and therefore clinicians and pathologists sent 
samples for this part of the study only when they had 
sufficient tissue for their routine pathological studies. 
The present study suggests that molecular detection of 
MMG and CEA markers by RT-PCR could be a powerful 
and sensitive complement to routine histopathological 
analysis. This study also suggests that the application of the 
two in combination would provide a higher detection rate. 
This approach needs good cooperation between surgeons, 
pathologists and molecular laboratories. Further evaluation 
in larger studies should help establish the clinical utility for 
breast cancer patient management. 
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